Phosphodiesterase- 4 (PDE4) inhibitors (Formulary)

APREMILAST

Important: Therapy notes

MHRA advice: Apremilast (Otezla): risk of suicidal thoughts and behaviour (January 2017) (www.gov.uk).

For NHS Highland Rheumatology Department GP and Patient information click here (NHSH intranet access required)

Important: Formulation and dosage details

Formulation:

Tablets in treatment initiation pack 10mg, 20mg, 30mg (hospital use only)

Important: Formulation and dosage details

Formulation:

Tablets 30mg (specialist initiation only)

Dosage:

Editorial Information

Document Id: F276